{"prefix":"ctcae","name":"Common Terminology Criteria for Adverse Events","description":"The Common Terminology Criteria for Adverse Events (CTCAE),[1] formerly called the Common Toxicity Criteria (CTC or NCI-CTC), are a set of criteria for the standardized classification of adverse effects of drugs used in cancer therapy. The CTCAE system is a product of the US National Cancer Institute (NCI).","pattern":"^E\\d+$","uri_format":"http://ncicb.nci.nih.gov/xml/owl/EVS/ctcae5.owl#$1","providers":[{"code":"bio2rdf","name":"Bio2RDF","description":"Bio2RDF is an open-source project that uses Semantic Web technologies to build and provide the largest network of Linked Data for the Life Sciences. Bio2RDF defines a set of simple conventions to create RDF(S) compatible Linked Data from a diverse set of heterogeneously formatted sources obtained from multiple data providers.","homepage":"https://bio2rdf.org","uri_format":"http://bio2rdf.org/ctcae:$1"}],"homepage":"https://evs.nci.nih.gov/ftp1/CTCAE/About.html","contact":{"name":"Yongqun Oliver He","orcid":"0000-0001-9189-9661","email":"yongqunh@med.umich.edu","github":"yongqunh"},"example":"E12768","example_extras":[],"download_owl":"http://aber-owl.net/media/ontologies/CTCAE/2/ctcae.owl","deprecated":false,"mappings":{"aberowl":"CTCAE","bioportal":"CTCAE","fairsharing":"FAIRsharing.dcsw6j","prefixcommons":"ctcae"},"synonyms":["CTCAE"],"keywords":["biomedical science","cancer","disease","ontology"],"references":["https://github.com/OAE-ontology/OAE/issues/8","https://en.wikipedia.org/wiki/Common_Terminology_Criteria_for_Adverse_Events"],"publications":[{"pubmed":"29854250","pmc":"PMC5977606","title":"Towards precision informatics of pharmacovigilance: OAE-CTCAE mapping and OAE-based representation and analysis of adverse events in patients treated with cancer drugs","year":2018},{"pubmed":"19379294","doi":"10.1111/j.1476-5810.2004.0053b.x","title":"Veterinary Co-operative Oncology Group - Common Terminology Criteria for Adverse Events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0","year":2004}],"appears_in":["oae"],"depends_on":[],"namespace_in_lui":false,"contributor":{"name":"Charles Tapley Hoyt","orcid":"0000-0003-4423-4370","email":"cthoyt@gmail.com","github":"cthoyt"},"preferred_prefix":"ctcae"}